Literature DB >> 15083071

Identification of two novel sequence variants affecting thiopurine methyltransferase enzyme activity.

Malin Lindqvist1, Sofie Haglund, Sven Almer, Curt Peterson, Jan Taipalensu, Erik Hertervig, Ebbe Lyrenäs, Peter Söderkvist.   

Abstract

The polymorphic enzyme thiopurine methyltransferase (TPMT) is involved in the methylation of thiopurines. On comparing the phenotype with the genotype in Swedish patients with inflammatory bowel disease and healthy individuals, we found two discordant cases with low TPMT enzyme activity (0.3 and 0.4 U/ml packed red blood cells (pRBC). Genotyping by pyrosequencing revealed that they carried the nucleotide substitutions 460G>A and 719A>G, giving two possible genotypes (TPMT*1/*3A or TPMT*3B/*3C). DNA sequencing of exon III to X was performed in the patients and their parents. We identified an A>G transition in the start codon (exon III, 1A>G, Met>Val, TPMT*14) in one of the patients and her father (6.3 U/ml pRBC). The mother in this family carried the 460G>A and 719A>G nucleotide substitutions (TPMT*1/*3A; 5.0 U/ml pRBC). In the second family, sequencing revealed a G>A transition in the acceptor splice site in intron VII/exon VIII (IVS7 -1G>A, TPMT*15) in the patient and his mother (6.9 U/ml pRBC). His father was genotyped as TPMT*1/*3A (6.0 U/ml pRBC). Hence, we report the identification of two novel sequence variants, present in highly conserved nucleotide positions of the human TPMT gene, resulting in a loss of enzyme activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15083071     DOI: 10.1097/00008571-200404000-00006

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  21 in total

Review 1.  Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.

Authors:  E G Quetglas; A Armuzzi; S Wigge; G Fiorino; L Barnscheid; M Froelich; Silvio Danese
Journal:  Eur J Clin Pharmacol       Date:  2015-05-27       Impact factor: 2.953

Review 2.  Pharmacogenomics: catechol O-methyltransferase to thiopurine S-methyltransferase.

Authors:  Richard M Weinshilboum
Journal:  Cell Mol Neurobiol       Date:  2006-06-29       Impact factor: 5.046

3.  Phenotyping and genotyping studies of thiopurine S-methyltransferase in Kazaks.

Authors:  Hong Wei; Shufeng Zhou; Chengrong Li; Jianping Zhang; Jueheng Wu; Min Huang
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

Review 4.  Pharmacogenetics in inflammatory bowel disease.

Authors:  Marie Pierik; Paul Rutgeerts; Robert Vlietinck; Severine Vermeire
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

Review 5.  Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.

Authors:  Tessa M Bosch; Irma Meijerman; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

6.  High-resolution melting analysis of the TPMT gene: a study in the Polish population.

Authors:  Marzena Skrzypczak-Zielinska; Pawel Borun; Katarzyna Milanowska; Ludwika Jakubowska-Burek; Oliwia Zakerska; Agnieszka Dobrowolska-Zachwieja; Andrzej Plawski; Ursula G Froster; Marlena Szalata; Ryszard Slomski
Journal:  Genet Test Mol Biomarkers       Date:  2012-12-19

7.  Relationships between thiopurine S-methyltransferase polymorphism and azathioprine-related adverse drug reactions in Chinese renal transplant recipients.

Authors:  Hua-Wen Xin; Hui Xiong; Xiao-Chun Wu; Qing Li; Lei Xiong; Ai-Rong Yu
Journal:  Eur J Clin Pharmacol       Date:  2008-12-02       Impact factor: 2.953

8.  Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease.

Authors:  U Hindorf; M Lindqvist; C Peterson; P Söderkvist; M Ström; H Hjortswang; A Pousette; S Almer
Journal:  Gut       Date:  2006-03-16       Impact factor: 23.059

9.  Four human thiopurine s-methyltransferase alleles severely affect protein structure and dynamics.

Authors:  Karen Rutherford; Valerie Daggett
Journal:  J Mol Biol       Date:  2008-04-18       Impact factor: 5.469

10.  IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations.

Authors:  Sofie Haglund; Jan Taipalensuu; Curt Peterson; Sven Almer
Journal:  Br J Clin Pharmacol       Date:  2007-07-27       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.